ahlam1399
03-12-2016, 06:31 AM
UPDATE 1-Infection worries prompt regulatory reviews of Gilead leukaemia drug
LONDON, March 11 (Reuters) - European and U.S. regulators are reviewing the safety of Gilead Sciences' leukaemia drug Zydelig due to concerns over serious adverse events, including deaths.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4e34c6c4/sc/13/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=13pq6bP5l3M:18b5iy4fsag:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=13pq6bP5l3M:18b5iy4fsag:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=13pq6bP5l3M:18b5iy4fsag:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=13pq6bP5l3M:18b5iy4fsag:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=13pq6bP5l3M:18b5iy4fsag:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/13pq6bP5l3M
LONDON, March 11 (Reuters) - European and U.S. regulators are reviewing the safety of Gilead Sciences' leukaemia drug Zydelig due to concerns over serious adverse events, including deaths.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4e34c6c4/sc/13/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=13pq6bP5l3M:18b5iy4fsag:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=13pq6bP5l3M:18b5iy4fsag:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=13pq6bP5l3M:18b5iy4fsag:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=13pq6bP5l3M:18b5iy4fsag:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=13pq6bP5l3M:18b5iy4fsag:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/13pq6bP5l3M